ViaLogy Corp. Appoints Douglas C. Lane, Chief Executive Officer.

Business Editors & Health/Medical Writers

PASADENA, Calif.--(BW HealthWire)--Oct. 11, 2001

ViaLogy Corp. announced today the appointment of Douglas C. Lane as Chief Executive Officer and Director of the company.

Lane's executive management and corporate development experience

Lane's experience base in the pharmaceutical and biotechnology industry includes corporate development positions at the former SmithKline Beecham Pharmaceuticals Research and Development and SmithKline Beecham Clinical Laboratories. He was Vice President of Corporate Development for Hyseq, Inc. (Nasdaq:HYSQ) and Vice President at CaP CURE, working with Michael Milken to advance genetic and genomic understanding of prostate cancer. Additionally, Lane was President, Chief Executive Officer, and Director of Strata Biosciences, a functional genomics company that was based in the San Francisco Bay Area. Lane holds a B.A. in Psychology, B.S. in Microbiology and Biochemistry, and an M.B.A. in Finance.

"We are excited that Doug has joined ViaLogy," said Dr. Carl Kukkonen, Chairman of ViaLogy and former Director of The Center for Space Microelectronic Technology at the Caltech/NASA Jet Propulsion Laboratory. "Doug's industry and management background fully complements our outstanding technical and scientific team. He adds measurably to ViaLogy's ability to successfully position and launch the company's computational microarray performance-enhancing products within the drug discovery and development industry."

"I am very delighted to have the opportunity to join this outstanding company," said Lane. "ViaLogy discovered and patented a breakthrough technology that detects ultra-weak signals emitted from gene fragments hybridized to DNA microarrays that are magnitudes lower than background noise of the microarray device itself. ViaLogy provides a paradigm shift in the life sciences which will lead to new scientific and medical discoveries."

ViaLogy is an early-stage technology company that discovered and developed a revolutionary active signal processing technology. Using its patented Quantum Resonance Interferometry, the company enables dramatic increases in detection sensitivity of DNA microarrays and other biochip platforms. ViaLogy is a portfolio company of ViaSpace Technologies LLC (see www.viaspace.com), formed to commercialize world-class technologies originating from the Caltech/NASA Jet Propulsion Laboratory and other government and University in Pasadena, Calif.